Forward to: Finance Team

Biotech Funding Intelligence
Workflows

Ten agent workflows for the Finance Team — IPO pipeline tracking, venture funding monitoring, grant intelligence, capital markets analysis, investor sentiment signals, biotech index analysis, secondary offering intelligence, debt financing tracking, crossover investor monitoring, and funding strategy dashboard — enabling data-driven financial decisions powered by domain intelligence.

1IPO Pipeline Tracking

AI agent monitors biotech company domains for IPO preparation signals — S-1 filings, underwriter engagement, audit completions, and board composition changes that indicate imminent public offerings.

1
Track IPO Preparation Signals
/investors/leadership/careersDomain AgesOpenPageRank
BIOTECH IPO PIPELINE — Q1 2026 ════════════════════════════════════════════════════════ S-1 FILED — IPO IMMINENT: example-biotech-ipo.com — mRNA Oncology /investors: S-1 filed — $200M target raise /leadership: Added 3 independent directors (public board prep) /careers: CFO + Controller + IR Director hired SIGNAL: IPO within 30 days — evaluate as investment IPO PREPARATION — 3-6 MONTHS OUT: stealth-gene-therapy.com /leadership: Big 4 audit firm engaged /careers: SOX compliance + IR postings Domain Age: 1,800 days | PageRank: 3.4 SIGNAL: IPO preparation — likely Q3 2026 IPO MARKET SUMMARY: Biotech IPOs (YTD 2026): 18 completed ($3.2B raised) Average first-day pop: +22% Pipeline: 24 S-1 filings pending

2Venture Funding Monitor

AI agent monitors biotech startup domains for venture funding signals — Series A through D rounds, lead investor identification, and capital deployment priorities.

1
Track Venture Funding Activity
/press/about/investorsDomain Ages
BIOTECH VENTURE FUNDING — Q1 2026 ════════════════════════════════════════════════════════ NOTABLE SERIES B+ ROUNDS: chroma-medicine.com — Epigenetic Editing /press: $135M Series B — led by ARCH + Flagship /about: 40 employees | Platform: gene silencing SIGNAL: Top-tier investors — validate epigenetic approach laronde.com — Endless RNA /press: $440M Series B — Flagship portfolio /about: Self-amplifying RNA platform SIGNAL: Massive round — potential platform disruptor VENTURE FUNDING SUMMARY: Total biotech VC (Q1 2026): $8.4B (+28% YoY) Median Series A: $48M | Series B: $120M Hot sectors: AI drug discovery, gene editing, obesity

3Grant Funding Intelligence

AI agent monitors NIH, BARDA, and other grant-funding agency domains to track non-dilutive funding opportunities, awarded grants, and government priorities in biotech and pharma research.

1
Track Grant Opportunities
/products/press/aboutCountries
GRANT FUNDING INTELLIGENCE ════════════════════════════════════════════════════════ nih.gov — NIH Funding /press: FY2026 budget: $48.5B (+3.2%) Priority areas: AI in drug discovery, pandemic preparedness SIGNAL: $2.1B allocated to ARPA-H — novel mechanisms medicalcountermeasures.gov — BARDA /products: 14 new BAAs published — MCM development /press: $800M for next-gen antiviral platforms OPPORTUNITY: $50-200M contracts available for our antiviral GRANT FUNDING AWARDED (OUR SECTOR): NIH R01 grants in our TAs: $340M this quarter BARDA contracts: $1.2B awarded YTD

4Capital Markets Analysis

AI agent monitors biotech capital markets activity by tracking secondary offerings, ATM programs, convertible debt issuances, and capital allocation strategies across the sector.

1
Analyze Capital Markets Activity
/investors/press/legalOpenPageRank
BIOTECH CAPITAL MARKETS — Q1 2026 ════════════════════════════════════════════════════════ SECONDARY OFFERINGS: Total raised (YTD): $12.8B across 45 offerings Average discount to market: 6.2% CONVERTIBLE DEBT: Issuance volume: $4.2B (8 deals) Average coupon: 2.8% | Average premium: 35% CASH RUNWAY RISK: Biotech companies with <12 months cash: 82 companies Likely capital raises next quarter: 28 expected SIGNAL: Capital-constrained biotechs may seek partnerships

5Investor Sentiment Tracking

AI agent monitors investor-focused biotech domains to track analyst ratings, price targets, institutional ownership changes, and conference attendance patterns as indicators of market sentiment.

1
Track Investor Sentiment
/investors/events/pressOpenPageRank
INVESTOR SENTIMENT INTELLIGENCE ════════════════════════════════════════════════════════ SECTOR SENTIMENT: XBI (Biotech ETF): +18% YTD — risk appetite improving IPO window: OPEN — strong demand for quality biotechs ANALYST COVERAGE CHANGES: Our company: 3 new coverage initiations (Buy/Outperform) Average price target: $85 — 32% upside INSTITUTIONAL OWNERSHIP: Baker Brothers: Increased position 15% OrbiMed: New position — $120M stake SIGNAL: Smart money accumulating — positive catalyst expected

6Crossover Investor Intelligence

AI agent monitors crossover investor activity — tracking late-stage private rounds led by public market investors as signals for upcoming IPOs and public company investment thesis.

1
Track Crossover Activity
/investors/press/aboutDomain Ages
CROSSOVER INVESTOR INTELLIGENCE ════════════════════════════════════════════════════════ CROSSOVER ROUNDS (LAST 90 DAYS): 8 biotech crossover rounds completed Total raised: $2.4B Top crossover investors: Fidelity, T Rowe, Wellington IPO PREDICTION FROM CROSSOVERS: Companies with crossover rounds → IPO within 12 months: 78% Average crossover-to-IPO timeline: 6-9 months SIGNAL: 6 of 8 crossover biotechs likely IPO 2026

7Competitor Financial Health

AI agent monitors competitor financial health by tracking cash positions, burn rates, debt maturities, and capital structure changes — identifying potential partnership or acquisition opportunities from distressed companies.

1
Assess Competitor Financial Health
/investors/press/careersOpenPageRank
COMPETITOR FINANCIAL HEALTH ASSESSMENT ════════════════════════════════════════════════════════ STRONG FINANCIAL POSITION: regeneron.com — Cash $12.4B | Net cash positive vertexpharm.com — Cash $10.8B | FCF $4.2B/year FINANCIALLY DISTRESSED: distressed-biotech.com /investors: Cash $45M | Burn rate $28M/quarter /careers: -60% postings — workforce reduction SIGNAL: 5-month runway — fire sale likely OPPORTUNITY: Pipeline asset worth $200-400M at steep discount DISTRESS METRICS: Companies with <6 months cash: 34 Expected wind-downs: 12 this year

8Debt Financing Tracker

AI agent monitors biotech debt financing activity — tracking royalty monetization, term loans, credit facilities, and revenue-based financing that indicate capital allocation strategies.

1
Track Debt Financing Activity
/investors/press/legalOpenPageRank
BIOTECH DEBT FINANCING TRACKER ════════════════════════════════════════════════════════ ROYALTY MONETIZATION: royaltypharma.com /investors: $2.8B deployed in 2025 | 12 new royalty assets /press: Acquired royalty on top-10 selling drug SIGNAL: Royalty financing attractive for non-dilutive capital VENTURE DEBT: herculescapital.com — $1.4B biotech portfolio Average term: 36 months | Rate: SOFR + 5-8% SIGNAL: Venture debt tightening — higher rates REVENUE-BASED FINANCING: Deals completed: 8 this quarter ($1.1B total) Average cost of capital: 12-18% implied

9Biotech Index & ETF Analysis

AI agent monitors biotech index composition, ETF flows, and sector rotation signals to provide macro-level intelligence on biotech investment trends and market positioning.

1
Analyze Biotech Sector Flows
/investors/products/pressIAB Categories
BIOTECH SECTOR ANALYSIS ════════════════════════════════════════════════════════ INDEX PERFORMANCE (YTD 2026): XBI (S&P Biotech ETF): +18% IBB (iShares Nasdaq Biotech): +14% NBI (Nasdaq Biotech Index): +15% ETF FLOWS: XBI: $2.4B inflows (last 3 months) IBB: $1.8B inflows SIGNAL: Sector rotation into biotech — risk appetite returning SECTOR VALUATION: XBI EV/Revenue: 4.8x (vs 5-year avg 5.2x) SIGNAL: Below historical average — value opportunity

10Funding Strategy Dashboard

AI agent synthesizes all funding intelligence into an executive dashboard — providing leadership with visibility into capital markets, competitor financial health, and fundraising environment.

1
Generate Funding Dashboard
/investors/press/aboutOpenPageRankIAB Categories
FUNDING DASHBOARD — FEBRUARY 2026 ════════════════════════════════════════════════════════ MARKET CONDITIONS: IPO window: OPEN | Investor sentiment: Positive XBI performance: +18% YTD FUNDRAISING ENVIRONMENT: VC funding (Q1): $8.4B (+28% YoY) IPOs completed: 18 ($3.2B raised) Secondary offerings: 45 ($12.8B raised) DISTRESSED OPPORTUNITIES: Companies <6 months cash: 34 Potential fire sale assets: $2-4B estimated value
2
Generate Funding Report

Biotech Funding Report — February 2026

EXECUTIVE SUMMARY ──────────────────────────────────────── Companies monitored for funding signals: 1,800 domains IPO filings tracked: 24 pending VC rounds monitored: 140+ this quarter Distressed biotechs: 34 with <6 months cash KEY INSIGHTS Biotech capital markets significantly improved — IPO window open. Crossover investor activity accelerating — 8 rounds completed. Distressed biotechs creating acquisition opportunities at discount. Grant funding priorities shifting toward AI and pandemic preparedness. Royalty monetization emerging as preferred non-dilutive financing.
Get in Touch

Interested in AI Agent Domain Intelligence?

For pricing, subscription options, custom database builds, or enterprise partnerships — contact us below.

Power Your AI Agents with Domain Intelligence

Subscribe to the AI Agent Domain Database — continuous access to 100M+ domains, 20 page types each, quarterly refreshes, and real-time change signals.

AI Agent Database View Pricing

Annual subscription includes quarterly data refreshes, change detection alerts, and priority API access.